Gilead Sciences, Inc. or Telix Pharmaceuticals Limited: Who Leads in Yearly Revenue?

Gilead vs. Telix: A Decade of Revenue Dominance

__timestampGilead Sciences, Inc.Telix Pharmaceuticals Limited
Wednesday, January 1, 20142489000000028336824
Thursday, January 1, 20153263900000032319194
Friday, January 1, 20163039000000029404631
Sunday, January 1, 20172610700000031769230
Monday, January 1, 20182212700000020439380
Tuesday, January 1, 20192244900000024186536
Wednesday, January 1, 2020246890000004680000
Friday, January 1, 2021273050000004898000
Saturday, January 1, 202227281000000155984000
Sunday, January 1, 202327116000000496659000
Monday, January 1, 202428754000000
Loading chart...

Unleashing insights

Gilead Sciences vs. Telix Pharmaceuticals: A Revenue Showdown

In the competitive landscape of pharmaceuticals, revenue growth is a key indicator of success. Over the past decade, Gilead Sciences, Inc. has consistently outperformed Telix Pharmaceuticals Limited in annual revenue. From 2014 to 2023, Gilead's revenue peaked in 2015, reaching approximately $32.6 billion, while Telix's highest revenue was around $497 million in 2023. This stark contrast highlights Gilead's dominance, with revenues often exceeding Telix's by over 500 times.

Despite Telix's impressive growth, particularly in 2023 with a 219% increase from the previous year, Gilead's established market presence and consistent revenue stream underscore its leadership. As the pharmaceutical industry evolves, it will be intriguing to see if Telix can continue its upward trajectory and close the gap with industry giants like Gilead.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025